Milos Miljkovic Sells 932 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Stock

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) insider Milos Miljkovic sold 932 shares of Cartesian Therapeutics stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $16.72, for a total transaction of $15,583.04. Following the sale, the insider now owns 36,341 shares in the company, valued at approximately $607,621.52. The trade was a 2.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Milos Miljkovic also recently made the following trade(s):

• On Monday, January 6th, Milos Miljkovic sold 948 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.83, for a total transaction of $15,954.84.
• On Thursday, November 14th, Milos Miljkovic sold 35,000 shares of Cartesian Therapeutics stock. The stock was sold at an average price of $16.13, for a total transaction of $564,550.00.

Cartesian Therapeutics Stock Performance

NASDAQ RNAC opened at $17.16 on Wednesday. The business’s 50 day moving average price is $19.22 and its 200-day moving average price is $18.15. Cartesian Therapeutics, Inc. has a fifty-two week low of $11.66 and a fifty-two week high of $41.87. The company has a market cap of $436.12 million, a P/E ratio of -0.32 and a beta of 0.56.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its holdings in shares of Cartesian Therapeutics by 122.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company’s stock worth $27,000 after acquiring an additional 909 shares during the last quarter. Point72 DIFC Ltd purchased a new stake in Cartesian Therapeutics in the 2nd quarter worth about $47,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Cartesian Therapeutics in the second quarter worth about $49,000. Barclays PLC boosted its position in shares of Cartesian Therapeutics by 208.6% during the third quarter. Barclays PLC now owns 11,611 shares of the company’s stock valued at $188,000 after buying an additional 7,849 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Cartesian Therapeutics during the second quarter valued at approximately $351,000. Institutional investors own 86.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on RNAC shares. Cantor Fitzgerald raised Cartesian Therapeutics to a “hold” rating in a report on Monday, December 2nd. BTIG Research started coverage on Cartesian Therapeutics in a research note on Thursday, December 19th. They issued a “buy” rating and a $42.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective (up from $41.00) on shares of Cartesian Therapeutics in a report on Wednesday, December 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $41.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, December 3rd. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.86.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.